Previous 10 | Next 10 |
BeiGene (NASDAQ:BGNE) said the China National Medical Products Administration (NMPA) granted conditional approval to tislelizumab to treat adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors. Th...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Inflation gets worse Check out Wall Street Breakfast's new Seeking Alpha show The Weekend Bite! On this week's episode we discuss the one stock to buy righ...
Tislelizumab is now approved in seven indications in China BeiGene, Ltd . (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patie...
Chinese Internet stocks such as JD.com (NASDAQ:JD), Alibaba (NYSE:BABA) and Baidu (NASDAQ:BIDU) dove into the red, Thursday, as the Securities and Exchange Commission named five companies from China that could be de-listed for failing to abide by U.S. accounting regulations. The SEC said YumC...
Shares of Chinese pharmas Zai Lab (ZLAB -18.7%) and BeiGene (BGNE -12.2%) are down significantly in early afternoon trading amid allegations they are in violation of a U.S. law preventing ownership by foreign governments. The drop comes as the companies were identified Wednesday as in po...
BeiGene (NASDAQ:BGNE) medicine Brukinsa was approved by Health Canada to treat adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. The company said it was the third approved indication for Brukinsa (zanubrutinib) in Canada, follo...
Follows U.S. approval for relapsed or refractory marginal zone lymphoma in 2021 Third approved indication for BRUKINSA in Canada, following mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM) BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235...
BeiGene develops drugs designed to fight cancer using molecular targeting and immuno-oncology technologies. The company boasts 11 self-developed drugs tested in 100 clinical trials in 35 different countries. Recently, BeiGene received FDA approval for a new prescription Leukemia d...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Cowen 42nd...
BeiGene press release (NASDAQ:BGNE): Q4 GAAP EPADS of -$6.16 misses by $1.29. Revenue of $214M (+113.8% Y/Y) beats by $0.64M. Cash, Cash Equivalents, Restricted Cash and Short-Term Investments were $6.62 billion as of December 31, 2021, compared to $3.92 billion as of September 30, 2021, and ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...